Nocturnal enuresis (NE), commonly known as bed-wetting, affects millions of school-age children worldwide, often leading to significant psychological distress and social challenges. An updated expert consensus, published in the World Journal of Pediatrics, now offers a comprehensive framework for clinicians to better diagnose and treat this condition. The new guidelines, developed by researchers from the Children's Hospital of Fudan University and the Chinese Cooperative Group for the Management of Pediatric NE, lower the diagnostic threshold and emphasize a phenotype-driven approach to therapy.
Traditionally, NE was diagnosed when a child aged five or older wet the bed at least twice a week for three consecutive months. The updated consensus reduces this frequency to at least one involuntary nighttime void per month for three months. This change allows for earlier intervention, potentially preventing the negative impacts on self-esteem and social functioning that often accompany persistent bed-wetting. The authors note that NE arises from multiple factors, including excessive nighttime urine production, reduced bladder capacity, and difficulty waking to bladder signals.
The consensus distinguishes between monosymptomatic NE (MNE), where no daytime urinary symptoms are present, and non-monosymptomatic NE (NMNE), which includes daytime symptoms such as urgency or incontinence. This classification is crucial because it guides treatment decisions. For MNE, the guidelines recommend phenotype-specific first-line therapy: desmopressin for nocturnal polyuria and enuresis alarms for reduced bladder capacity. For mixed types, combination therapy is suggested. For NMNE, the focus shifts to treating daytime lower urinary tract symptoms and comorbidities, especially constipation, which affects 36–80% of these children.
A key component of the new framework is the voiding diary, which requires patients to record at least two daytime charts and seven consecutive nights of fluid intake and voids. This helps clinicians phenotype the child's condition and tailor treatment accordingly. The consensus also establishes clear referral criteria: primary care providers can manage MNE, but non-responders or those with suspected NMNE should be referred for specialist evaluation, including urodynamics and lumbosacral MRI. For refractory cases, defined as less than 50% improvement after three months, the guidelines advise a systematic re-evaluation of adherence, diary findings, and potential underlying causes before escalating treatment.
Dr. [Author Name], lead author of the consensus, emphasized that NE should not be treated as a uniform disorder. “Our updated pathway asks clinicians to identify the child's specific pattern, look for daytime symptoms and comorbidities, and match treatment to the likely underlying mechanism while keeping the family involved,” they said. The authors also stressed that apparent treatment failure should trigger a careful review before adding stronger therapy.
The recommendations are expected to reduce trial-and-error treatment and improve response rates by promoting earlier attention to constipation, sleep-disordered breathing, ADHD, and daytime urinary symptoms. The framework also supports better coordination between primary and specialist care, ensuring timely referrals when needed. However, the authors acknowledge that some recommendations reflect Chinese practice patterns and that evidence for certain aspects, like desmopressin withdrawal strategies, remains limited. Future research and multidisciplinary care models could further refine individualized treatment approaches.
This updated consensus represents a significant step forward in standardizing care for pediatric nocturnal enuresis, offering a practical roadmap that can be adapted globally. By emphasizing early diagnosis and individualized treatment, it aims to improve outcomes and quality of life for affected children and their families.
